HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPA Internal Review Sparked Suit Against Board Members, Ongoing Changes

This article was originally published in The Rose Sheet

Executive Summary

A review launched after NPA's former CFO filed a wrongful termination complaint in November has invalidated the allegations, but has "also shown that there was some governance that needed to change," says Executive Director and CEO Daniel Fabricant.

You may also be interested in...



NPA, Ex-CFO Weickert Exchange Unsavory Allegations In Legal Crossfire

In lawsuits pending in DC District Court, former NPA CFO Brent Weickert claims he was wrongfully terminated after raising concerns with the trade group's board about CEO Daniel Fabricant's conduct, while NPA is suing to remove board members who allegedly conspired with Weickert to oust Fabricant and serve their own personal interests.

NPA Maintains Limits On Retailer Membership

A proposed change would have removed the requirement that retail members have stores and that 75% of their sales come from natural foods, supplements and related items. But NPA members approved five bylaw amendments to simplify the process of voting for board members.

US OTC Switch Drought Ends: FDA Approves GSK Arthritis Gel, Alcon Allergy Eye Drops

FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.

Topics

UsernamePublicRestriction

Register

RS019832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel